“Gilead Secures Bernstein’s Outperform, Medicaid Risk Contained”
Bernstein SocGen Group maintains a positive Outperform rating on Gilead Sciences, asserting limited financial risk amid Medicaid pricing changes. Primarily affecting Genvoya and Odefsey drugs, which represent a minority portion of their portfolio, Gilead's revenue stability shows resilience to these adjustments, instilling investor assurance. Read more
Read More
“H.C. Wainwright Holds Neutral View on Biohaven Following BHV-7000 Hiccup”
Biohaven's disappointing clinical trial results for depression drug BHV-7000 reaffirm the firm's neutral rating by H.C Wainwright. As BHV-7000 fails to hit primary and secondary endpoints, it highlights the volatile nature of pharma R&D. Despite setbacks, Biohaven's potential in immunology, obesity, and epilepsy research remains promising. Read more
Read More“Biohaven Faces H.C. Wainwright’s Neutral View After BHV-7000 Hurdles”
Biohaven Pharmaceutical (NYSE: BHVN) holds steady with a Neutral rating from H.C. Wainwright, despite its recent drug, BHV-7000's, underwhelming trials for treating major depressive disorder. Undeterred, Biohaven unveils a resilient strategy redirecting focus to immunology, obesity, and epilepsy, maintaining a promising presence in the biotech market. Read more
Read More